0000000000225648

AUTHOR

Elena Sabattini

0000-0002-4136-3591

showing 12 related works from this author

Burkitt lymphoma with a granulomatous reaction: an M1/Th1‐polarised microenvironment is associated with controlled growth and spontaneous regression

2021

Aims Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that, in some instances, may show a granulomatous reaction associated with a favourable prognosis and occasional spontaneous regression. In the present study, we aimed to define the tumour microenvironment (TME) in four such cases, two of which regressed spontaneously. Methods and results All cases showed aggregates of tumour cells with the typical morphology, molecular cytogenetics and immunophenotype of BL surrounded by a florid epithelioid granulomatous reaction. All four cases were Epstein-Barr virus (EBV)-positive with type I latency. Investigation of the TME showed similar features in all four cases. The analysis revealed a p…

MaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanHistologyAdolescentM1 polarised macrophagesTh1 T cellsExpressionBiologyT-Cell ResponsesVirusPathology and Forensic MedicineProinflammatory cytokineMolecular cytogeneticsOriginImmunophenotypingEBVM1 polarised macrophagehemic and lymphatic diseasesTumor MicroenvironmentmedicineHumansM1 polarized macrophagesAgedInhibitionMacrophagesBurkitt lymphomaBurkitt lymphoma; EBV; In Situ lymphoid neoplasia; M1 polarized macrophages; Microenvironment; Th1 T cells; granulomatous reactionB-CellsGeneral MedicineMiddle AgedTh1 Cellsmedicine.diseaseBurkitt LymphomamicroenvironmentRegressionLymphomain-situ lymphoid neoplasiagranulomatous reactionCancer researchFemaleTherapyCellular immunotherapyInfectionEarly phaseBurkitt lymphoma EBV granulomatous reaction in-situ lymphoid neoplasia M1 polarised macrophages microenvironment Th1 T cellsIn Situ lymphoid neoplasiaEpstein-Barr-VirusHistopathology
researchProduct

A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era. Selecting cases, matching clinical bene…

2019

An accurate diagnosis of clinically distinct subgroups of aggressive mature B cell lymphomas is crucial for the choice of proper treatment. Presently, precise recognition of these disorders relies on the combination of morphological, immunophenotypical, and cytogenetic/molecular features. The diagnostic workup in such situations implies the application of costly and time-consuming analyses, which are not always required, since an intensified treatment option is reasonably reserved to fit patients. The Italian Group of Haematopathology proposes herein a practical algorithm for the diagnosis of aggressive mature B cell lymphomas based on a stepwise approach, aimed to select cases deserving mo…

0301 basic medicinemedicine.medical_specialtyMatching (statistics)Lymphoma B-CellLymphomadouble hitComputer scienceMYCDouble hitFluorescencePathology and Forensic MedicineImmunophenotyping03 medical and health sciences0302 clinical medicineFISHDiagnosismedicinePractical algorithmHumansIntensive care medicineB-cell lymphomaMolecular BiologyIn Situ HybridizationIn Situ Hybridization FluorescenceHGBLBrief ReportB-CellTreatment optionsCorrectionDiagnosis; DLBCL; Double hit; FISH; HGBL; MYC; Humans; Immunophenotyping; In Situ Hybridization Fluorescence; Lymphoma B-Cell; AlgorithmsCell BiologyGeneral MedicineDiagnosis DLBCL Double hit FISH HGBL MYCmedicine.diseaseDiagnosis; DLBCL; double hit; FISH; HGBL; MYCOptimal managementMolecular analysis030104 developmental biology030220 oncology & carcinogenesisDLBCLPosition paperProper treatmentAlgorithmsDiagnosiHuman
researchProduct

Pathobiology of Hodgkin Lymphoma

2010

Despite its well-known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognizes a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (cHL), reflecting the differences in clinical presentation and behavior, morphology, phenotype, and molec…

Pathologymedicine.medical_specialtybusiness.industryMixed cellularityLymphocyteHematologyReview ArticleHistogenesismedicine.diseasePhenotypeVirusLymphomaPathobiologymedicine.anatomical_structurehemic and lymphatic diseasesmedicineHodgkin lymphomaDiseases of the blood and blood-forming organsRC633-647.5businessWho classificationHodgkin lymphoma; microenvironment.Hodgkin lymphomamicroenvironment.Advances in Hematology
researchProduct

Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical an…

2009

Abstract Abstract 4974 Background The bone marrow trephine biopsy (BMB) has a crucial role for the diagnosis of essential thrombocythemia (ET), both according to the PVSG and the WHO criteria. The WHO 2001 criteria enhanced the role of BMB also by distinguishing the true-ET (ET) from the prefibrotic and the early fibrotic chronic idiopathic myelofibrosis. The WHO 2008 criteria, in the JAK2 era, confirmed the diagnostic and prognostic relevance of the histopathological features in ET as well as in the other Ph-neg myeloproliferative neoplasms (MPN). Otherwise, only few validated data are presently available, and the reproducibility in the evaluation of some morphological details is still con…

medicine.medical_specialtymedicine.diagnostic_testEssential thrombocythemiabusiness.industryPipobromanImmunologyCell BiologyHematologyAnagrelidemedicine.diseaseBiochemistryGastroenterologyGroup BSurgeryPolycythemia veraInternal medicineBiopsymedicinebusinessMyelofibrosisBusulfanmedicine.drugBlood
researchProduct

Peripheral T-cell lymphoma classification: the matter of cellular derivation.

2011

Peripheral T-cell lymphomas (PTCLs) represent approximately 12% of all non-Hodgkin's lymphomas in Western countries. They are quite heterogeneous as far as morphology and phenotype are concerned. Furthermore, until now, PTCLs could not be referred to specific normal counterparts, in contrast to B-cell-derived non-Hodgkin's lymphomas. In particular, in the last edition of the WHO classification of Tumors of the Hematopoietic and Lymphoid Tissues, for the majority of nodal PTCLs (including the not otherwise specified type and anaplastic large-cell lymphoma), the postulated cell of origin remained undefined. However, in the last few years, high-throughput genomic techniques, especially gene-ex…

T cellGene Expression ProfilingNot Otherwise SpecifiedT lymphocytesLymphoma T-Cell PeripheralTfhHematologyBiologymedicine.diseasePhenotypePeripheral T-cell lymphomaLymphomaGene expression profilingcytotoxicgene-expression profilemedicine.anatomical_structureImmunologymedicineCancer researchCytotoxic T cellHumansProspective Studiesperipheral T-cell lymphomaTumors of the hematopoietic and lymphoid tissuesExpert review of hematology
researchProduct

Pediatric Anaplastic Large Cell Lymphoma with Concomitant Involvement of Spine and Central Nervous System: A Case Report and Review of Literature

2021

Anaplastic large cell lymphoma (ALCL) is a histological subtype of non-Hodgkin lymphoma, largely characterized by anaplastic lymphoma kinase (ALK) positivity, resulting from the chromosomal translocation t(2;5). We report a pediatric case of ALK-positive ALCL with primary concomitant involvement of bone and central nervous system (CNS); thereafter, a literature review about pediatric primary bone and primary CNS ALCL was conducted. According to the analyzed data, our case is unique because it is characterized by the contemporary involvement of the spine and CNS. During and after chemotherapy, our patient was monitored by detecting minimal residual disease (MRD) through the analysis of fusio…

ChemotherapyPathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentRcentral nervous systemmedicine.diseaseboneMinimal residual diseaseLymphomamedicine.anatomical_structureFusion transcriptanaplastic large cell lymphomahemic and lymphatic diseasesConcomitantminimal residual diseasemedicineMedicineAnaplastic lymphoma kinaseBone marrowbusinessAnaplastic large-cell lymphomaHemato
researchProduct

Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas

2017

Abstract Follicular dendritic cell (FDC) sarcomas are rare mesenchymal tumors with variable clinical, morphologic, and phenotypic characteristics. Transcriptome analysis was performed on multiple FDC sarcomas and compared with other mesenchymal tumors, microdissected Castleman FDCs, and normal fibroblasts. Using unsupervised analysis, FDC sarcomas clustered with microdissected FDCs, distinct from other mesenchymal tumors and fibroblasts. The specific endowment of FDC-related gene expression programs in FDC sarcomas emerged by applying a gene signature of differentially expressed genes (n = 1,289) between microdissected FDCs and fibroblasts. Supervised analysis comparing FDC sarcomas with mi…

0301 basic medicineAlgorithms; B7-H1 Antigen; Castleman Disease; Chromatin; Cluster Analysis; Dendritic Cell Sarcoma Follicular; Gene Expression Profiling; Gene Expression Regulation Neoplastic; Humans; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Signal Transduction; T-Lymphocytes Helper-Inducer; T-Lymphocytes Regulatory; Up-Regulation; Gene Regulatory Networks; Molecular Biology; Oncology; Cancer ResearchCancer ResearchProgrammed Cell Death 1 ReceptorDendritic Cell Sarcoma FollicularBiologyT-Lymphocytes RegulatoryB7-H1 AntigenTranscriptome03 medical and health sciencesmedicineCluster AnalysisHumansGene Regulatory NetworksMolecular BiologyRegulation of gene expressionCluster AnalysiGene Regulatory NetworkFollicular dendritic cellsCastleman DiseaseGene Expression ProfilingMesenchymal stem cellT-Lymphocytes Helper-InducerProgrammed Cell Death 1 Ligand 2 Proteinmedicine.diseaseChromatinUp-RegulationAlgorithmGene Expression Regulation NeoplasticGene expression profiling030104 developmental biologyOncologyCancer researchImmunohistochemistrySarcomaAlgorithmsHumanSignal TransductionExtracellular matrix organizationMolecular Cancer Research
researchProduct

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

2018

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P<.0001). In particular, twenty-five epigenetic-modifiers were found mutated (e.g., ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of …

Acute Myeloid LeukemiaBlastic plasmacytoid dendritic cell neoplasm epigenetic mutationsSkin NeoplasmsAzacitidineDecitabinePlasmacytoid dendritic cellGene mutationBiologyDecitabineBPDCNArticleEpigenesis Genetic03 medical and health sciences0302 clinical medicineHistone methylation5’-Azacytidine; Acute Myeloid Leukemia; BPDCN; Decitabine; WESmedicineHumansEpigeneticsExome sequencingRegulation of gene expressionMyeloproliferative DisordersDendritic CellsGenomicsHematology5 -AzacytidineMyeloid Neoplasms5’-AzacytidineCancer researchWES030215 immunologymedicine.drugHaematologica
researchProduct

Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm

2021

Simple Summary For the first time, neuronal features are described in blastic plasmacytoid dendritic cell neoplasm (BPDCN) by a complex array of molecular techniques, including microRNA and gene expression profiling, RNA and Chromatin immunoprecipitation sequencing, and immunohistochemistry. The discovery of unexpected neural features in BPDCN may change our vision of this disease, leading to the designing of a new BPDCN cell model and to re-thinking the relations occurring between BPDCN and nervous system. The observed findings contribute to explaining the extreme tumor aggressiveness and also to propose novel therapeutic targets. In view of this, the identification, in this work of new po…

Cancer ResearchNeurogenesisNeoplasms. Tumors. Oncology. Including cancer and carcinogensMicroRNA Expression ProfilesequencingBiologySettore MED/08 - Anatomia PatologicaBPDCN MiRNA Network Neurogenesis SequencingBPDCNArticleChromatinGene expression profilingBPDCN; MiRNA; Network; Neurogenesis; SequencingneurogenesisOncologyDownregulation and upregulationmicroRNAnetworkCancer researchImmunohistochemistrySettore MED/05 - Patologia ClinicaNeurogenesiRC254-282ProgenitormiRNACancers
researchProduct

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified

2014

Peripheral T-cell lymphomas not otherwise specified (PTCLs/NOS) are rare and aggressive tumours whose molecular pathogenesis and diagnosis are still challenging. The microRNA (miRNA) profile of 23 PTCLs/NOS was generated and compared with that of normal T-lymphocytes (CD4+, CD8+, naive, activated). The differentially expressed miRNA signature was compared with the gene expression profile (GEP) of the same neoplasms. The obtained gene patterns were tested in an independent cohort of PTCLs/NOS. The miRNA profile of PTCLs/NOS then was compared with that of 10 angioimmunoblastic T-cell lymphomas (AITLs), 6 anaplastic large-cell lymphomas (ALCLs)/ALK+ and 6 ALCLs/ALK - . Differentially expressed…

Female; Gene Expression Profiling; Humans; Lymphoma T-Cell Peripheral; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; RNA Neoplasm; Gene Expression Regulation Neoplastic; Oncology; Hematology; Medicine (all)Malemedicine.medical_specialtyPathologyPeripheral T-cell lymphoma not otherwise specifiedBiologyhemic and lymphatic diseasesInternal medicinemicroRNAmedicineHumansRNA NeoplasmOligonucleotide Array Sequence AnalysisRegulation of gene expressionHematologymicroRNA; PTCLs/NOS; GEPOligonucleotide Array Sequence AnalysiGene Expression ProfilingMedicine (all)Not Otherwise SpecifiedLymphoma T-Cell PeripheralMicroRNAHematologymedicine.diseaseGEPLymphomaGene expression profilingGene Expression Regulation NeoplasticMicroRNAsOncologyPTCLs/NOSOriginal ArticleFemaleCD8Human
researchProduct

Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Pre…

2005

Abstract Ninety ET patients diagnosed according to the PVSG criteria were enrolled in a phase II study (sponsored by the Schering-Plough Company) designed to evaluate the efficacy, safety and tolerability of a two years treatment with PEG Interferon alpha-2 b (PEG Intron). The patients, observed in 16 Italian Centres belonging to the GIMEMA Cooperative Group and judged at high risk, had been previously treated with cytoreductive (97%) and antiplatelet (91%) drugs. At the study start the patients, 60 F and 30 M, mean age 45 years, showed splenomegaly in 22% of cases. The Hematological Response (HR: PLT<500 x109/L) was observed in 64/81 (79%) and 48/55 (87%) of the patients on PEG Intr…

medicine.medical_specialtythrombocythemia (ET) patientsImmunologyEssential Thrombocythemia (ET); PEG Interferon alpha-2b.Phases of clinical researchAlpha (ethology)BiochemistryGastroenterologyPEG Interferon alpha-2bFibrosisInternal medicinePEG ratioBiopsyMedicineEssential Thrombocythemia (ET)medicine.diagnostic_testbusiness.industryEssential thrombocythemiaCell BiologyHematologymedicine.diseaseSurgerymedicine.anatomical_structureTolerabilityBone marrow evaluationBone marrowbusiness
researchProduct

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

2014

This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocitemie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO classification for the diagnosis of the Philadelphia chromosome-negative myeloproliferative neoplasms. A series of 103 bone marrow biopsy samples of Philadelphia chromosome-negative myeloproliferative neoplasms consecutively collected in 2004 were classified according to the WHO criteria as follows: essential thrombocythaemia (n=34), primary myelofibrosis (n=44) and polycythaemia vera (n=25). Two independent groups of pathologists reviewed the bone marrow biopsies. The first group w…

AdultMalePolycythaemiaPathologymedicine.medical_specialtymyeloproliferative neoplasmPhiladelphia Chromosome Negativeessential thrombocythaemiaWorld Health Organizationpolycythaemia veramyeloproliferative neoplasmsPathology and Forensic MedicineYoung AdultCohen's kappaBone Marrowhemic and lymphatic diseasesBiopsyHumansMedicinePhiladelphia ChromosomeMyelofibrosisPolycythemia VeraAgedAged 80 and overObserver VariationWHO classificationmedicine.diagnostic_testbusiness.industryprimary myelofibrosiReproducibility of ResultsMiddle Agedmedicine.diseaseprimary myelofibrosisFemaleWho criteriaDifferential diagnosisessential thrombocythaemia; myeloproliferative neoplasms; primary myelofibrosis; polycythaemia vera; WHO classificationbusinessWho classificationThrombocythemia EssentialModern Pathology
researchProduct